What is the difference between slow granules and chronic granules, and what are the medicines of slo

1. The causes of the disease are different.

Chronic myeloid leukemia.

The ** is still unclear, but the Philadelphia chromosome is thought to be.

Closely related to the disease, about 90 to 95% of patients develop the Philadelphia chromosome.

Chronic myelomonocytic leukemia.

Chronic myelomonocytic leukaemia (CMML) is a chronic myeloid leukemia. The incidence is about 1 2 100 000 years, most of which occur after the age of 60, and the ratio of males to females is about 1.

Specific** unknown. There is no specificity.

chromosomal ectopia.

2. Clinical manifestations:

Chronic myelogenous leukemia is asymptomatic in the early stages, and blood counts are usually checked for other reasons.

and was discovered. The symptoms that appear can be divided into signs of hyperproliferation and hypermetabolism; White blood cell.

markedly increased, signs of tissue infiltration; There are three types of signs that normal hematopoietic tissue is affected. fatigue, weight loss, low-grade fever.

Symptoms such as night sweats may disappear when cell proliferation is controlled by drugs.

A common clinical symptom of chronic myelomonocytic leukemia is fever.

Infection, bleeding, fatigue, weight loss, night sweats, etc., about half of patients have hepatosplenomegaly. The median survival of patients with CMML is about 20 months, and survival may be related to the proportion of bone marrow blasts. There is currently no method for special effects.

3. **Different schemes:

Chronic myelogenous leukemia is now mostly chemical. For the chronic phase of chronic granules, busulfan tablets are the drug of choice. This drug is easy to apply, less effective, and has high efficacy.

In the absence of a better way to support CRM, support is critical for CMML. Most patients with CMML are older and often have other medical conditions, and support is particularly important. Most patients cannot tolerate intense chemotherapy.

The full name of chronic myelomonocytic leukemia is chronic myelomonocytic leukemia, abbreviated as CMML. It is a clonal disease of bone marrow hematopoietic stem cells, which is characterized by significant proliferation of bone marrow granules and monocytes, and an increase in monocytes in peripheral blood (>1 10 9 l). In the 2001 WHO classification of hematopoietic and lymphocytic tumors, CMML is classified as myelodysplastic syndrome (MDS), which is characterized by both pathological hematopoietic and myeloproliferative features.

Chronic myeloid leukemia accounts for 95% of chronic leukemia in yellow Asians. Eventually, myelofibrosis, acute leukemia and multiple organ failure, complicated by infection, bleeding and other serious complications were complicated. The course of the disease varies widely, from as short as 1-2 years, to 5-10 years, or even 20 years.

Slow granules is a kind of chronic leukemia, the development process is relatively slow, but there are also patients who have just been diagnosed in the accelerated stage, if the patient is positive for the BCR abl gene, you can take Gleevec**, but the Internet can only provide you with suggestions, specific **plan, or should go to a regular hematology hospital to receive regular**.

Disease analysis: Slow granules are effective**is: chemical**, radiation**, splenectomy.

Suggestions: Chemotherapy: BUS (Maryland), HU (hydroxyurea), CTX, CLB, 6 MP (6 mercaptopurine), MMC (mitomycin). Among them, BUS was the preferred drug, followed by HU.

Blood count: the white blood cell count is high above 100 10 9 L, and most of the blood films are neutrophil rod nuclei and late myelocytes, and the rest are lobulated nuclei, mesomyelocytes, promyelocytes and a few myeloblasts. Eosinophils and basophils are also increased.

Hemoglobin and red blood cells are mildly reduced in the early stages, platelets are normal or increased, and red blood cells and platelets are reduced in the late stages. It must be differentiated from leukemia-like reactions in terms of blood count.

Bone marrow image: bone marrow hyperplasia is obvious to extremely active, cell classification is similar to that of peripheral blood, bone marrow films, granulocytes can be seen in various stages, among which the middle and late granules are the mainstay, progranulocytes and protomyelocytes are more than normal, but generally not more than 5% 10%, eosinophil and (or) basophilia are increased, the red blood cell line is relatively reduced, granules: red about 10 50:

1. Erythrocytes and megakaryocytes often increase in the early stage and decrease in the late stage. Alkaline phosphatase activity in mature neutrophils was significantly reduced in 90% of patients. Chromosomal examination:

The ph' chromosome is present in more than 90% of patients with chronic granules. The PH chromosome is considered to be the tumor marker of chronic granulous pluripotent stem cells, and a small number of patients with chronic granules are negative for PH chromosome, and the prognosis of the former is better than that of the latter. Blood Biochemistry:

Serum vitamin B12 concentration and vitamin B12 binding capacity > significantly increased as one of the characteristics of the disease, and the increase was proportional to the degree of leukocytosis. The elevated level is due to the excessive production of transcobalamin I, which transports vitamin B12, by a large number of normal and leukemic granulocytes. Serum uric acid concentrations can be elevated, especially during chemotherapy.

The full name of chronic myeloid leukemia is chronic myeloid leukemia. Chronic granulocyte is a myeloproliferative disorder characterized by a marked increase in granulocytes (including mature and naïve granulocytes), a marked enlargement of the spleen, and the vast majority of relatively specific pH-marker chromosomes, with a slow course of the disease. In the early stages of the disease, these cells are capable of differentiation and the bone marrow is functioning normally.

The disease usually remains stable for several years and eventually becomes more malignant, with most cases of acute death. The majority of patients with this disease are between 30 and 40 years old, and those under 20 years old are rare.